Labcorp Holdings Inc. LH

Company Overview

Labcorp Holdings Inc. is a global life sciences and healthcare diagnostics company headquartered in Burlington, North Carolina. The company operates primarily through laboratory testing services and drug development support, serving healthcare providers, hospitals, pharmaceutical companies, biotechnology firms, government agencies, and patients. Labcorp is widely recognized as one of the largest clinical laboratory networks in the world and operates across the diagnostics, biopharma, and clinical trial support industries. Its primary revenue drivers include routine and specialty diagnostic testing, central laboratory services for clinical trials, companion diagnostics, and drug development support services.

The company traces its origins to Roche BioMedical and National Health Laboratories, which merged in 1995 to form Laboratory Corporation of America Holdings. Over time, Labcorp expanded through acquisitions and strategic integrations, including the acquisition of Covance in 2015, which significantly expanded its drug development and clinical research capabilities. In 2023, Labcorp completed the spin-off of its clinical development business into Fortrea Holdings Inc., reshaping the company’s strategic focus toward diagnostics and laboratory services. The company’s scale, broad testing menu, payer relationships, and extensive laboratory infrastructure provide competitive advantages in both routine diagnostics and specialized testing markets.

Business Operations

Labcorp primarily operates through two major business segments: Diagnostics Laboratories and Biopharma Laboratory Services. The Diagnostics Laboratories segment provides routine and specialty testing services, including oncology, women’s health, genetic testing, autoimmune diagnostics, and infectious disease testing. Revenue is generated through reimbursement arrangements with managed care organizations, government healthcare programs, hospitals, employers, physicians, and direct-to-consumer channels. The Biopharma Laboratory Services segment supports pharmaceutical and biotechnology companies with central laboratory services, companion diagnostics, and clinical trial testing solutions.

Labcorp maintains extensive domestic operations throughout the United States and also operates internationally across Europe, Asia-Pacific, Latin America, and parts of the Middle East and Africa. The company controls a large laboratory network, logistics infrastructure, specimen transport systems, and proprietary diagnostic technologies. Key subsidiaries and operating entities include Labcorp Diagnostics, Covance, and specialized testing businesses acquired over time. Labcorp has maintained strategic collaborations with hospital systems, health insurers, and pharmaceutical manufacturers to expand testing access and support precision medicine initiatives.

Strategic Position & Investments

Labcorp’s strategic direction has increasingly emphasized advanced diagnostics, precision medicine, oncology testing, and decentralized clinical trial support. Following the separation of Fortrea Holdings Inc., the company has focused on strengthening its diagnostics platform, expanding specialty testing capabilities, and improving operational efficiency. Investments have included automation technologies, digital health tools, at-home specimen collection solutions, and expanded genetic and molecular testing capacity.

The company has historically pursued growth through acquisitions and partnerships designed to broaden its testing portfolio and geographic reach. Notable acquisitions have included Covance, Personal Genome Diagnostics, and several regional laboratory operations. Labcorp also continues to invest in companion diagnostics and biomarker development to support pharmaceutical partners developing targeted therapies. Emerging areas of focus include artificial intelligence-enabled diagnostics, precision oncology, and expanded biopharma laboratory services supporting advanced therapeutics and cell and gene therapy development.

Geographic Footprint

Labcorp operates across more than 100 countries through laboratory facilities, service centers, clinical trial operations, and partnerships. Its headquarters are located in Burlington, North Carolina, with major operational presence throughout North America, Europe, and Asia-Pacific. The company maintains one of the largest laboratory networks in the United States, supported by regional laboratories, specialty testing facilities, and patient service centers nationwide.

Internationally, Labcorp supports pharmaceutical and biotechnology clients through global central laboratory operations and clinical trial services. The company maintains operational and investment influence in key healthcare and biopharma markets including the United Kingdom, Germany, China, Japan, Singapore, and Brazil. Its global infrastructure allows it to support multinational clinical studies, cross-border testing programs, and integrated laboratory services for healthcare systems and life sciences companies.

Leadership & Governance

Labcorp is governed by a board of directors and executive leadership team focused on operational efficiency, innovation in diagnostics, and long-term healthcare partnerships. The company’s leadership strategy has emphasized expanding high-growth specialty testing areas while improving productivity and integrating advanced technologies into laboratory operations. Corporate governance practices are disclosed through annual filings including the company’s SEC Form 10-K and proxy statements.

Key executives include:

• Adam H. Schechter – Chair and Chief Executive Officer
• Glenn A. Eisenberg – Executive Vice President and Chief Financial Officer
• Brian J. Caveney, M.D. – Chief Medical and Scientific Officer
• Mark S. Schroeder – Executive Vice President and President, Diagnostics Laboratories
• Bill Haas – Senior Vice President, Corporate Development and Strategy
• Kerrii B. Anderson – Lead Independent Director

Leadership has consistently communicated a strategy centered on innovation in diagnostics, operational scale, scientific partnerships, and long-term growth in specialty testing and biopharma services. Information regarding executive responsibilities and governance structure is consistently reflected across company filings, investor materials, and public disclosures.